Northern Italy Leukemia Group
Quick facts
Phase 2 pipeline
- Chemotherapy-Rituximab combination · Oncology
Rituximab targets CD20 on B cells
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: